Projects

SCRIP (Study of Cardiovascular Risk Intervention by Pharmacists):
A Study of the Effect of Community Pharmacist Identification, Assessment and Intervention on Cardiac Risk Factor Modification Practices.

 

Study Objective:

To determine the efficacy of a program of intervention by community pharmacists in high risk coronary heart disease (CHD) patients on lipid-risk management.

Principal Investigator:

Tsuyuki, R.T.

Co-Investigators:

Status:

Completed, published (see Publications below)

Editorial:

Pharmacy Practice, May 2003

Publications:

1. Tsuyuki RT, Johnson JA, Teo KK, Ackman ML, Biggs R, Cave A, Chang W-C, Dzavik V, Farris KB, Semchuk W, Simpson SH, Taylor J, for the SCRIP Investigators. Study of Cardiac Risk Intervention by Pharmacists (SCRIP): A Randomized Trial Design of the Effect of a Community Pharmacist Intervention Program on Serum Cholesterol Risk. Ann Pharmacother 1999;33:910-9.

2. Simpson SH, Johnson JA, Tsuyuki RT. Economic Impact of Community Pharmacist Intervention in Cholesterol Risk Management: An Evaluation of the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). Pharmacotherapy 2001;21(5):627-635.

3. Simpson SH, Johnson JA, Biggs C, Biggs RS, Kuntz A, Semchuk W, Taylor JG, Farris KB, Tsuyuki RT, for the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP) Investigators. Practice-Based Research: Lessons From Community Pharmacist Participants. Pharmacotherapy 2001;21(6):731-739.

4. Tsuyuki RT, Johnson JA, Teo KK, Simpson SH, Ackman ML, Biggs RS, Cave AJ, Chang W-C, Dzavik V, Farris KB, Galvin D, Semchuk W, Taylor JG. A Randomized Trial of the Effect of Community Pharmacist Intervention on Cholesterol Risk: The Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). Arch Int Med 2002;162:1149-1155.

Abstracts:

1. Tsuyuki RT, Johnson JA, Teo KK, Ackman ML, Biggs R, Cave A, Chang W-C, Dzavik V, Farris K, Galvin D, Semchuk W, Simpson SH, Taylor JG, for the SCRIP Investigators. Design of the Study of Cardiac Risk Intervention by Pharmacists (SCRIP): A Study of the Effect of Community Pharmacist Identification, Assessment, and Intervention on Cardiac Risk Factor Modification Practices. Presented: Canadian Pharmacoepidemiology Forum, Ottawa, ON, April 27-28, 1998. Published: Can J Clin Pharmacol 1998; 5: 68. Presented: Canadian Pharmacists' Association 86th Annual Meeting, St. John's, NF, May 25, 1998. Published: Conference Proceedings. Presented: Canadian College of Clinical Pharmacy 6th Annual Symposium (research finalist), Whistler, BC, June 6, 1998. Published: Conference Proceedings. Presented: Canadian College of Clinical Pharmacy 6th Annual Symposium (research finalist), Whistler, BC, June 6, 1998. Published: Conference Proceedings.

2. Simpson SH, Johnson JA, Teo KK, Tsuyuki RT. Design of an Economic Evaluation of the Study of Coronary Risk Intervention by Pharmacists (SCRIP). Presented: Canadian College of Clinical Pharmacy 6th Annual Symposium, Whistler, BC, June 6, 1998. Published: Conference Proceedings.

3. Simpson SH, Biggs C, Galvin D, Johnson J, Kuntz A, Semchuk W, Taylor J, Tsuyuki RT, for the SCRIP Investigators. Establishment and Management of the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP) Network of Community Pharmacies. Presented: Canadian Society of Hospital Pharmacists Western Provinces Banff Seminar, March 17-19, 2000. Published: Conference Proceedings.

4. Tsuyuki RT, Johnson JA, Teo KK, Simpson SH, Ackman ML, Biggs RS, Cave AJ, Chang W-C, Dzavik V, Farris KB, Galvin D, Semchuk W, Taylor JG, for the SCRIP Investigators. A Randomized Trial of the Effect of Community Pharmacist Intervention on Cholesterol Risk: The Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). Presented: Canadian Cardiovascular Society 53rd Annual Meeting, Vancouver, October 29 - November 1, 2000. Published: Can J Cardiol 2000;16(Suppl F):118F. Presented: American Heart Association 73rd Scientific Sessions, New Orleans, LA, November 12-15, 2000. Published: Circulation 2000;192(18):II-873-874. Presented: American College of Clinical Pharmacy, Los Angeles, November 8, 2000. Published: Pharmacother 2000;20(10):1231. Presented: North American Primary Care Research, Amelia Island, Florida, November 6, 2000. Published: Conference Proceedings.

5. Simpson SH, Johnson JA, Tsuyuki RT, for the SCRIP Investigators. Economic Evaluation of a Community Pharmacy Intervention Program to Improve the Management of Cholesterol Risk. Presented: Canadian Cardiovascular Society 53rd Annual Meeting, Vancouver, October 29 - November 1, 2000. Published: Can J Cardiol 2000;16(Suppl F):118F. Presented: American College of Clinical Pharmacy, Los Angeles, November 6, 2000. Published: Pharmacother 2000;20(10):1258.

6. Simpson SH, Johnson JA, Biggs C, Biggs RS, Kuntz A, Semchuk W, Taylor JG, Farris KB, Tsuyuki RT, for the SCRIP Investigators. Lessons learned from community pharmacists who have participated in practice-based research. Presented: The Canadian Association for Population Therapeutics, Banff, April 1-3, 2001. Published: Can J Clin Pharmacol 2001;8:33.

7. Cave AJ, Johnson JA, Simpson SH, Lau T, Farris KB, Tsuyuki RT for the SCRIP Investigators. Physician responses to community pharmacist intervention in cholesterol risk management. Presented: The Canadian Association for Population Therapeutics, Banff, April 1-3, 2001. Published: Can J Clin Pharmacol 2001;8:35. Presented: American College of Clinical Pharmacy, Salt Lake City, Utah, April 22-25, 2001. Published: Pharmacotherapy 2001;21(3)379-380.

8. Simpson SH, Johnson JA, Tsuyuki RT, for the SCRIP Investigators. Community pharmacist intervention improves cholesterol risk management in people with diabetes: An evaluation of the study of cardiovascular risk intervention by pharmacists (SCRIP). Presented: Canadian Diabetes Association/Canadian Society of Endocrinology and Metabolism Professional Conference and Annual Meeting, Edmonton, October 17-20, 2001. Published: Can J Diab Care 2001;25:227